Stratos Genomics closes Series-A financing deal

Stratos Genomics Inc. today announced it has closed a Series-A financing deal of $4 million to continue development of its ultra-low-cost nucleic acid sequencing method for whole genome analysis and molecular diagnostics. The round was led by Fisk Ventures and included Stratos Group LLC.

"In the midst of the current, highly-charged genomic sequencing market, this investment in Stratos Genomics is an important statement. It indicates not only the validity of the technology but confidence in our future success," Stratos Genomics CEO, Allan Stephan, said. "We are pleased to have the support of Fisk Ventures as we continue developing technology that will play an important role in the future of medicine and genomic sciences."

"The Stratos Genomics technology has the potential to revolutionize personalized medicine and bring genome sequencing technology to all. If our goals are realized, Stratos Genomics will have a huge impact on life sciences," Stephen Rose, Managing Director of Fisk Ventures, said.